Compare Abeona Therapeutics Inc (ABEO) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Hyatt Hotels Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Hyatt Hotels Corporation trades at $189 (market cap $18.19B). The key difference: Hyatt Hotels Corporation is far larger — about 48.7× Abeona Therapeutics Inc's market cap, and Hyatt Hotels Corporation pays a 0.31% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | H | |
|---|---|---|
Market Cap | $373.32M | $18.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $202.09 |
52-Week Low | $4.17 | $135.01 |
Enterprise Value | $228.22M | $22.03B |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Hyatt Hotels (H) trades at $193.16, up 0.98% with a neutral technical signal. The stock shows mixed fundamentals with negative net income margins (-0.48%) and ROE (-1.02%) despite revenue growth to $7.1B in 2025. Recent earnings beat expectations in Q4 2025 and Q1 2026, while analyst consensus targets $197.30. The company continues expansion with new hotel announcements and maintains strong institutional support.
Investment outlook is cautiously optimistic given analyst buy ratings (37.5%) and expansion initiatives, but risks include declining cash flow trends and elevated debt levels. The stock faces pressure from negative profitability metrics despite revenue stability, requiring careful monitoring of upcoming Q2 2026 earnings against the $0.89 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
